What Is CagriSema? Dosage, Half-Life & How to Track It

What CagriSema is and how it works

CagriSema combines two mechanisms that work through genuinely different receptors: semaglutide activates the GLP-1 receptor, slowing gastric emptying and quieting appetite signaling through the gut-brain axis, while cagrilintide activates amylin receptors in the brainstem, a separate satiety pathway. The idea behind the combination is that two non-redundant appetite signals produce more weight loss than either drug pushed to its own maximum dose alone.

Early Phase 2 data supported that idea, with weight loss exceeding semaglutide alone. The larger Phase 3 REDEFINE trial program showed real but more modest results than the early data suggested — around 20% average weight loss at 68 weeks in the flagship trial, ahead of semaglutide alone but below the roughly 25% some had projected from Phase 2. Novo Nordisk has continued pursuing regulatory submission on the strength of that data.

Because both components are already individually approved or in late-stage development — semaglutide as Ozempic/Wegovy, cagrilintide as CagriSema’s other half — CagriSema’s open questions are less about basic safety and more about incremental benefit versus semaglutide alone. Its approval status can change; check current regulatory status before assuming availability.

Typical dosing & titration

The approved-format pen co-delivers both compounds at a matched dose, so titration moves both up together rather than requiring separate schedules the way manually stacking cagrilintide onto an existing semaglutide regimen would:

• Weeks 1–4: 0.25/0.25 mg
• Weeks 5–8: 0.5/0.5 mg
• Weeks 9–12: 1.0/1.0 mg
• Weeks 13–16: 1.7/1.7 mg
• Weeks 17+: 2.4/2.4 mg (maintenance)

The approved pen delivers a fixed co-dose with no reconstitution required. This table reflects the math for a compounded or research-vial format, where each compound is reconstituted and dosed to match — the calculator handles either.

Half-life & what it means for frequency

Cagrilintide and semaglutide were chosen as combination partners partly because their half-lives are nearly identical — both around 7 days — so a single weekly injection keeps both signals elevated on the same schedule instead of one component outlasting the other.

As with any compound in this half-life range, levels build across the first several weeks of a new dose before reaching steady state, and the effect does not disappear quickly after stopping — expect several weeks of tapering appetite suppression as both components clear.

What to track & common side effects

Trial data shows the same GI side-effect profile as the individual components — nausea, constipation, diarrhea — and, notably, did not show a meaningfully worse GI burden than semaglutide alone despite adding a second mechanism, one of the more reassuring findings from the Phase 3 program.

The tracking priorities mirror any weekly GLP-class compound: dose and titration step so escalation is deliberate, weight and waist as a trend, and protein intake, since a dual-pathway appetite suppressant makes under-eating protein easy to do without noticing.

Frequently asked questions